
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is currently performing well, showing signs of a strong recovery in both their 1Q'26 and future FY'26 revenue, specifically in China where they are expected to generate approximately $144.4M, positioning them as leaders in a fast-growing $3.4 billion refractive surgery device market. Their Collamer lens technology, with over 40 years of experience and 3 million lenses implanted globally, gives them a competitive advantage in the industry and their recent rebound in gross margin and expectation of positive adjusted EBITDA further supports a positive outlook.
Bears say
Staar Surgical is facing challenges in its key market of China and may struggle to sustain its recent increase in net sales. Additionally, changes in leadership and competition from domestic manufacturers pose risks for the company. While there is potential for growth in its niche market, concerns about operational performance and potential liquidity constraints may hinder the company's success in the long term.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares